Abstract
Neurokinins are known to induce neurogenic inflammation related to respiratory diseases. The effects of CS-003 ([1-{2-[(2R)-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl}spiro[benzo[c]thiophene-1(3H),4'-piperidine]-(2S)-oxide hydrochloride]), a novel triple neurokinin receptor antagonist, on several respiratory disease models were evaluated in guinea pigs. As we have already shown that CS-003 is intravenously effective, we first determined if CS-003 was orally effective. CS-003 dose-dependently inhibited substance P-induced tracheal vascular hyperpermeability, neurokinin A- and neurokinin B-induced bronchoconstriction with ID(50) values of 3.6, 1.3 and 0.89 mg/kg (p.o.), respectively. CS-003 (10 mg/kg, p.o.) inhibited the number of coughs induced by capsaicin aerosol (P<0.01) and the antitussive effect was comparable to that of codeine. CS-003 (10 mg/kg, p.o.) also inhibited airway hyperresponsiveness to methacholine chloride in ovalbumin-induced asthma models (P<0.01), a milder one and a severer one. On the other hand, montelukast (10 mg/kg, p.o.), a leukotriene receptor antagonist, significantly inhibited the hyperresponsiveness only in the milder model (P<0.05). In an ovalbumin-induced rhinitis model, ...Continue Reading
References
Dec 1, 1990·The Journal of Physiology·H P KuoD F Rogers
Sep 1, 1991·The American Review of Respiratory Disease·G BraunsteinN Frossard
Dec 1, 1988·British Journal of Pharmacology·D F RogersP J Barnes
Jan 1, 1995·Progress in Neurobiology·C A Maggi
Aug 1, 1993·Journal of Molecular Endocrinology·I M AdcockP J Barnes
Feb 1, 1993·Journal of Autonomic Pharmacology·C A MaggiA Giachetti
Jul 1, 1996·Experimental Lung Research·P BalukJ A Nadel
Aug 26, 1998·Thorax·L G HeaneyC Shaw
Feb 24, 2001·Lancet·M J LeckieP J Barnes
Sep 14, 2001·Respirology : Official Journal of the Asian Pacific Society of Respirology·P N ReynoldsM D Holmes
Oct 6, 2001·American Journal of Respiratory Cell and Molecular Biology·K KwongL Y Lee
Jun 10, 2003·Annals of the New York Academy of Sciences·Guy F JoosRomain A Pauwels
Jun 19, 2004·International Archives of Allergy and Immunology·Osamu MukaiyamaMakoto Yamashita
Sep 8, 2004·Treatments in Respiratory Medicine·Stuart B Mazzone
Jan 22, 2005·European Journal of Pharmacology·Akihiro TagawaYoshiaki Ishigatsubo
Aug 23, 2005·Proceedings of the American Thoracic Society·Diana C Grootendorst, Klaus F Rabe
Nov 4, 2005·Proceedings of the American Thoracic Society·Bradley J Undem, Marian Kollarik
Dec 21, 2005·Pulmonary Pharmacology & Therapeutics·V SchelfhoutG Joos
Apr 25, 2006·The Journal of Allergy and Clinical Immunology·Jaclyn SmithAshley Woodcock
Citations
Mar 2, 2011·The Journal of Reproduction and Development·Ken-ichi NoritakeHiroko Tsukamura
Jan 12, 2016·COPD·Hala S Abdel Kawy
May 26, 2012·International Journal of Pediatric Otorhinolaryngology·Ozkaya EminDundaroz M Rusen
Jun 29, 2010·Neuropeptides·Zsuzsanna HelyesJohn P Quinn
Oct 13, 2009·Pharmacology & Therapeutics·Julie Nasra, Maria G Belvisi
Mar 19, 2009·Pharmacology & Therapeutics·Tibor Z VeresArmin Braun
Dec 14, 2011·Expert Opinion on Therapeutic Patents·Maria Altamura
Jul 3, 2013·Pulmonary Pharmacology & Therapeutics·Stefano FogliMaria Cristina Breschi
Mar 29, 2014·Pharmacological Reviews·P V DicpinigaitisC P Page
Sep 13, 2019·Medicinal Research Reviews·Angeliki P KourounakisAriadni Tzara
Jun 6, 2020·Clinical Science·Mikael AdnerSven-Erik Dahlén
May 22, 2019·The Journal of Antibiotics·Ken-Ichi Kimura